pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

innocoll PRESS RELEASE ARCHIVE

Sep 26, 2022

Innocoll and DURECT Announce U.S. launch of POSIMIR

Jul 6, 2022

Innocoll Announces Publication of Positive Results from Pivotal Clinical Trial of POSIMIR in Arthroscopic Subacromial Decompression

Mar 2, 2022

Innocoll Announces Positive Topline Results For XARACOLL (bupivacaine hydrochloride) implant in a Phase 3 Study to Support Expanded Use

Jan 28, 2022

Innocoll Announces Successful Completion of Debt Refinancing

Apr 14, 2021

Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll (bupivacaine hydrochloride) Implant

Feb 4, 2021

Anthony Galdi Appointed Chief Commercial Officer of Innocoll

Jan 11, 2021

Louis Pascarella Appointed Chief Executive Officer of Innocoll

Oct 29, 2020

Innocoll Announces Commercial Launch of XARACOLL (bupivacaine HCI) implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults

Mar 26, 2020

Innocoll Holdings Limited Announces FDA Acceptance of New Drug Application for XARACOLL for the Management of Postsurgical Pain after Open Inguinal Hernia Surgery

Feb 27, 2020

Innocoll Holdings Limited Resubmits New Drug Application to FDA for XARACOLL for the Management of Postsurgical Pain after Open Inguinal Hernia Surgery

Mar 5, 2019

Innocoll Holdings Limited Appoints Richard Fante as Chief Executive Officer

Jul 24, 2017

Gurnet Point L.P. Completes Acquisition of Innocoll Holdings plc

Jul 24, 2017

Innocoll and Gurnet Point Announcement relating to the Scheme becoming Effective

Jul 7, 2017

Technical Snapshots for These Generic Drugs Stocks -- Mallinckrodt, Patheon, Zoetis, and Innocoll

Jun 28, 2017

Innocoll Announces Scheme Meeting and Extraordinary General Meeting Voting Results

Jun 5, 2017

Breakfast Technical Briefing on Generic Drugs Stocks -- Innocoll, Rigel Pharma, Tetraphase Pharma, and Catalent

Apr 18, 2017

Research Reports Coverage on Generic Drugs Stocks -- Innocoll, Catalyst Pharma, Galectin Therapeutics, and Tetraphase Pharma

Apr 4, 2017

Gurnet Point L.P. enters into agreement to acquire Innocoll Holdings plc

Apr 4, 2017

Recommended Offer for Innocoll Holdings PLC by Gurnet Point L.P. Acting Through Its General Partner Waypoint International GP LLC

Mar 29, 2017

Innocoll announces regulatory path forward after receiving formal FDA Type A meeting minutes regarding its XARACOLL (bupivacaine HCl collagen-matrix implant) New Drug Application

Mar 24, 2017

Lifshitz and Miller LLP Announces Investigation of Aratana Therapeutics, Inc., FXCM Inc., Innocoll Holdings plc, Momenta Pharmaceuticals, Inc., Omnicom Group Inc., Perrigo Company plc, Santander Consumer USA Holdings Inc. and The Interpublic Group of Companies, Inc.

Mar 21, 2017

INNL ALERT: Rosen Law Firm Reminds Innocoll Holdings plc Investors of Important March 27 Deadline in First-Filed Case by Firm - INNL

Mar 16, 2017

Innocoll Holdings plc Announces Fourth Quarter and Full-Year 2016 Financial and Operating Results and Provides Corporate Update

Mar 13, 2017

Research Reports Coverage on Generic Drugs Stocks -- Galectin Therapeutics, Catalyst Pharma, Innocoll, and Tetraphase Pharma

Mar 13, 2017

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Innocoll Holdings plc - INNL

Mar 10, 2017

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Innocoll Holdings Public Limited Company of Class Action Lawsuit and Upcoming Deadline – INNL

Mar 3, 2017

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Innocoll Holdings Public Limited Company of Class Action Lawsuit and Upcoming Deadline - INNL

Mar 3, 2017

INNL SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Innocoll Holdings plc and a Lead Plaintiff Deadline of March 27, 2017

Jan 31, 2017

INNL LOSS ALERT: Rosen Law Firm Reminds Innocoll Holdings plc Investors of Important Deadline in First-Filed Case by Firm

Jan 25, 2017

SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Notifies Investors of Class Action Against Innocoll Holdings, plc (INNL) and Lead Plaintiff Deadline: March 27, 2017

Jan 24, 2017

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Innocoll Holdings plc and Encourages Investors with Losses to Contact the Firm

Dec 30, 2016

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innocoll Holdings plc - INNL

Dec 30, 2016

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Innocoll Holdings plc - INNL

Dec 29, 2016

Innocoll Receives Refusal to File Letter from U.S. FDA for XARACOLL (bupivacaine HCl collagen-matrix implants) New Drug Application

Nov 3, 2016

Innocoll Announces Top-Line Data From Phase 3 Trials With COGENZIA and NDA Submission for XARACOLL

Aug 17, 2016

Innocoll Holdings plc Announces Second Quarter 2016 Financial and Operating Results and Provides Corporate Update

Aug 11, 2016

Innocoll to Report Second Quarter 2016 Financial Results and Host Webcast and Conference Call on August 17, 2016

Jun 23, 2016

Innocoll Holdings plc Announces the Completion of Enrollment in Two Pivotal Phase 3 Clinical Trials of COGENZIA for the Treatment of Diabetic Foot Infections

Jun 16, 2016

Innocoll Holdings plc Announces Pricing of Public Offering of Ordinary Shares

May 25, 2016

Innocoll Announces XARACOLL (bupivacaine-collagen bioresorbable implant) Meets Primary Endpoint in Both Pivotal Phase 3 Trials in Postoperative Pain Relief

Aug 13, 2015

Innocoll AG Appoints Rich Fante as Chief Commercial Officer and Head of Business Development

Apr 1, 2015

Pivotal Pharmacokinetic Study of Innocoll's XaraColl(R) Supports Use of 300 mg Dose for Phase 3 Clinical Studies in Post-Operative Pain

Mar 19, 2015

Innocoll AG Announces Fourth Quarter and Full Year 2014 Financial and Operating Results

Aug 4, 2014

Citi Appointed Depositary Bank for Innocoll’s ADR Programme

Jul 25, 2014

Innocoll AG Announces Pricing of Initial Public Offering

Apr 3, 2012

Innocoll Provides Update of Regulatory and Partnering Activities for CollaGUARD Adhesion Barrier and Launches New Product Website

Feb 17, 2012

Innocoll Announces Successful End-of-Phase 2 Meeting with FDA for XaraColl and Agreement of the Phase 3 Program

Feb 1, 2012

Innocoll Enters CollaGUARD Distribution Partnership With Flynn Pharma Ltd in the UK and Inresa Arzneimittel GmbH in Germany

Nov 15, 2011

Innocoll Enters Partnership with Merus Labs in Canada for the Distribution of CollaGUARD

Oct 19, 2011

Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD

Oct 11, 2011

Innocoll Announces European Approval for CollaGUARD, Surgical Adhesion Barrier

Google Analytics Alternative